trial Fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, with increasing prevalence in the aging population. About 2.2 million patients in the United States and 4.5 million patients within the European Union have AF. 1 The most feared and devastating complications of AF are thromboembolism and ischemic stroke. About 15-20 % of patients suffering from AF develop strokes. 2 In view of an aging population, the higher physiological propensity for bleeding in the elderly and the overwhelming issues of polypharmacy, the decision for the use of anticoagulation is critical.
Andrade et al. 3 compared the conflicting guidelines of anticoagulation (recommended by the European Society of Cardiology guidelines) versus no anticoagulation (recommended by the American College of Chest Physicians guidelines) in patients aged 65 to 74 years who had AF with a CHADS2 score of 0 and without any contraindication for anticoagulation using real-world outcomes of stroke, intracranial hemorrhages, and extracranial hemorrhages. They found no benefit for anticoagulation with a number needed to treat with warfarin to prevent one stroke of 333. This expansion of warfarin use would cause about 44 extracranial hemorrhages per 333 patients. Since 7 % of these extracranial hemorrhages were fatal, expanding warfarin use would cause roughly three fatal extracranial hemorrhages per one ischemic stroke prevented. Adding anticoagulation to the regimen of this patient population using the European Society of Cardiology guidelines would lead to a 10 % increase in the use of anticoagulation.
The most recent ACC/AHA 4 guidelines recommend using the CHA2DS2-VASc score in this particular patient group.
Patients with a score of 0 can omit antithrombotic therapy. Those with a score of 1 can receive either aspirin or no antithrombotic therapy. Prospectively, it will be interesting to see real-world outcomes using the CHA2DS2-VASc score, particularly the choice of anticoagulation versus aspirin based on the individual component of this score, as a select group of patients might benefit from aspirin more than anticoagulation depending on their comorbidities, and vice versa. Also, researchers should determine if novel anticoagulants with safer bleeding profiles will benefit this patient population in terms of stroke prevention.
